secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0000950170-25-094445
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports statistically significant Phase 2 REGEN-007 results for rilparencel; FDA Type B meeting set
--------------------------------------------------------------------------------

- eGFR slope improved 78% from -5.8 to -1.3 mL/min/1.73m² per year (p<0.001) in Group 1 (n=24).
- Group 2 showed 50% improvement but not statistically significant (p=0.085); evidence of dose response.
- No rilparencel-related serious adverse events observed; safety consistent with prior studies and kidney biopsy.
- FDA Type B meeting set for summer 2025 to confirm eGFR slope as surrogate endpoint for accelerated approval.
- Full results submitted to ASN 2025 Kidney Week as late-breaking clinical trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/0000950170-25-094445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025094445/prok-20250708.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-094445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer